Review of the role of refined dietary sugars (fructose and glucose) in the genesis of retinal disease

Clinical and Experimental Ophthalmology

Volumn 42, Issue 6, 2014, Pages 564-573

  Kearney, Frances M ^a,b   Fagan, Xavier J ^a   Al Qureshi, Salmaan ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Vision Centre Gold Coast   (Australia)

Author keywords

Diabetic retinopathy; Fructose; Metabolic syndrome; Retinal vascular disease; Sugar

Indexed keywords

CARBOHYDRATE; FRUCTOSE; GLUCOSE; CARBOHYDRATE DIET; SWEETENING AGENT;

ANTERIOR ISCHEMIC OPTIC NEUROPATHY; BIOCHEMISTRY; CATARACT; DIABETIC RETINOPATHY; EYE DISEASE; FOOD PROCESSING; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; HYPERTENSION RETINOPATHY; LIVER METABOLISM; METABOLIC SYNDROME X; MICROANGIOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; PUBLIC HEALTH PROBLEM; RETINA BLOOD FLOW; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SOFT DRINK; SUGAR INTAKE; SYRUP; CARBOHYDRATE DIET; HYPERTENSIVE RETINOPATHY; MACULAR DEGENERATION; OPTIC NEUROPATHY, ISCHEMIC;

CATARACT; DIABETIC RETINOPATHY; DIETARY CARBOHYDRATES; FRUCTOSE; GLUCOSE; HUMANS; HYPERTENSIVE RETINOPATHY; MACULAR DEGENERATION; OPTIC NEUROPATHY, ISCHEMIC; SWEETENING AGENTS;

EID: 84908356937     PISSN: 14426404     EISSN: 14429071     Source Type: Journal    
DOI: 10.1111/ceo.12290     Document Type: Review

References (97)

1. Krause MV, Mahan LK. Food, Nutrition and Diet Therapy, 7th edn. Philadelphia: WB Saunders Company, 1984.
2. Blass EM, Hoffmeyer LB. Sucrose as an analgesic for newborn infants. Pediatrics 1991; 87: 215-218.
3. Stanhope KL, Schwarz JM, Keim NL etal. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest 2009; 119: 1322-1334.
4. Bray GA. How bad is fructose? Am J Clin Nutr 2007; 86: 895-896.
5. Lustig RH. Fructose: it's 'alcohol without the buzz'. Adv Nutr 2013; 4: 226-235.
6. Lustig RH. Fructose: metabolic, hedonic, and societal parallels with ethanol. J Am Diet Assoc 2010; 110: 1307-1321.
7. Basu S, Yoffe P, Hills N, Lustig RH. The relationship of sugar to population-level diabetes prevalence: an econometric analysis of repeated cross-sectional data. PLoS ONE 2013; 8: e57873.
8. Duffey KJ, Popkin BM. High-fructose corn syrup: is this what's for dinner? Am J Clin Nutr 2008; 88: 1722S-1732.
9. Schorin MD. High fructose corn syrups, part 1: composition, consumption, and metabolism. Nutr Today 2005; 40: 248-252.
10. Lustig RH, Schmidt LA, Brindis CD. Public health: the toxic truth about sugar. Nature 2012; 482: 27-29.
11. Vos MB, Kimmons JE, Gillespie C, Welsh J, Blanck HM. Dietary fructose consumption among US children and adults: the Third National Health and Nutrition Examination Survey. Medscape J Med 2008; 10: 160.
12. Vartanian LR, Schwartz MB, Brownell KD. Effects of soft drink consumption on nutrition and health: a systematic review and meta-analysis. Am J Public Health 2007; 97: 667-675.
13. Green Pool Commodity Specialists. Sugar Consumption in Australia: A Statistical Update. Brisbane: Funded by Bundaberg Sugar, Manildra Harwood Sugars, Sugar Australia and CANEGROWERS, 2012.
14. McLennon W, Podger A. National Nutrition Survey: Foods Eaten. Canberra: Australian Bureau of Statistics, 1995.
15. Rikkers W, Lawrence D, Hafekost K, Mitrou F, Zubrick SR. Trends in sugar supply and consumption in Australia: is there an Australian Paradox? BMC Public Health 2013; 13: 668.
16. National Health and Medical Research Council. Australian dietary guidelines, Canberra, 2013.
17. COAG Reform Council. Healthcare 2011-12: comparing performance across Australia. 2013.
18. Monash Obesity & Diabetes Institute. Facts and figures. 2013. Accessed May 2013. Available from: http://www.modi.monash.edu.au/obesity-facts-figures/obesity-in-australia/
19. Alwan A, Armstrong T, Cowan M, Riley L. Noncommunicable diseases country profiles 2011. 2011. Accessed May 2013. Available from: http://whqlibdoc.who.int/publications/2011/9789241502283_eng.pdf
20. Bray GA, Nielsen SJ, Popkin BM. Consumption of high-fructose corn syrup in beverages may play a role in the epidemic of obesity. Am J Clin Nutr 2004; 79: 537-543.
21. Ludwig DS, Peterson KE, Gortmaker SL. Relation between consumption of sugar-sweetened drinks and childhood obesity: a prospective, observational analysis. Lancet 2001; 357: 505-508.
22. Maersk M, Belza A, Stodkilde-Jorgensen H etal. Sucrose-sweetened beverages increase fat storage in the liver, muscle, and visceral fat depot: a 6-mo randomized intervention study. Am J Clin Nutr 2012; 95: 283-289.
23. Tappy L, Lê K-A. Metabolic effects of fructose and the worldwide increase in obesity. Physiol Rev 2010; 90: 23-46.
24. Keys A. Coronary heart disease in seven countries. Circulation 1970; 41: 186-195.
25. Keys A. Seven Countries. A Multivariate Analysis of Death and Coronary Heart Disease. Cambridge, MA: Harvard University Press, 1980.
26. Lustig RH. Fat Chance: Beating the Odds Against Sugar, Processed Food, Obesity, and Disease. New York: Hudson Street Press, 2012.
27. Bremer AA, Mietus-Snyder M, Lustig RH. Toward a unifying hypothesis of metabolic syndrome. Pediatrics 2012; 129: 557-570.
28. Stanhope KL, Havel PJ. Endocrine and metabolic effects of consuming beverages sweetened with fructose, glucose, sucrose, or high-fructose corn syrup. Am J Clin Nutr 2008; 88: 1733S-1737.
29. Moodie R, Stuckler D, Monteiro C etal. Profits and pandemics: prevention of harmful effects of tobacco, alcohol, and ultra-processed food and drink industries. Lancet 2013; 381: 670-679.
30. Rizkalla SW. Health implications of fructose consumption: a review of recent data. Nutr Metab (Lond) 2010; 7: 82.
31. Topping D, Mayes P. The concentrations of fructose, glucose and lactate in the splanchnic blood vessels of rats absorbing fructose. Ann Nutr Metab 1971; 13: 331-338.
32. Moore MC, Davis SN, Mann SL, Cherrington AD. Acute fructose administration improves oral glucose tolerance in adults with type 2 diabetes. Diabetes Care 2001; 24: 1882-1887.
33. Décombaz J, Jentjens R, Ith M etal. Fructose and galactose enhance postexercise human liver glycogen synthesis. Med Sci Sports Exerc 2011; 43: 1964-1971.
34. Hudgins LC, Parker TS, Levine DM, Hellerstein MK. A dual sugar challenge test for lipogenic sensitivity to dietary fructose. J Clin Endocrinol Metab 2011; 96: 861-868.
35. Haber G, Heaton K, Murphy D, Burroughs L. Depletion and disruption of dietary fibre: effects on satiety, plasma-glucose, and serum-insulin. Lancet 1977; 310: 679-682.
36. Alberti KGM, Zimmet P, Shaw J. The metabolic syndrome - a new worldwide definition. Lancet 2005; 366: 1059-1062.
37. Kok N, Roberfroid M, Delzenne N. Dietary oligofructose modifies the impact of fructose on hepatic triacylglycerol metabolism. Metabolism 1996; 45: 1547-1550.
38. Perheentupa J, Raivio K. Fructose-induced hyperuricaemia. Lancet 1967; 290: 528-531.
39. Emmerson B. Effect of oral fructose on urate production. Ann Rheum Dis 1974; 33: 276-280.
40. Mazzali M, Hughes J, Kim Y-G etal. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001; 38: 1101-1106.
41. Thorburn AW, Storlien LH, Jenkins AB, Khouri S, Kraegen E. Fructose-induced in vivo insulin resistance and elevated plasma triglyceride levels in rats. Am J Clin Nutr 1989; 49: 1155-1163.
42. Hwang I-S, Ho H, Hoffman BB, Reaven GM. Fructose-induced insulin resistance and hypertension in rats. Hypertension 1987; 10: 512-516.
43. Bremer AA, Stanhope KL, Graham JL etal. Fructose-fed rhesus monkeys: a nonhuman primate model of insulin resistance, metabolic syndrome, and type 2 diabetes. Clin Transl Sci 2011; 4: 243-252.
44. Teff KL, Elliott SS, Tschöp M etal. Dietary fructose reduces circulating insulin and leptin, attenuates postprandial suppression of ghrelin, and increases triglycerides in women. J Clin Endocrinol Metab 2004; 89: 2963-2972.
45. Chanmugam P, Guthrie JF, Cecilio S, Morton JF, Basiotis PP, Anand R. Did fat intake in the United States really decline between 1989-1991 and 1994-1996? J Am Diet Assoc 2003; 103: 867-872.
46. Chiu CJ, Taylor A. Dietary hyperglycemia, glycemic index and metabolic retinal diseases. Prog Retin Eye Res 2011; 30: 18-53.
47. Thornalley PJ, Langborg A, Minhas HS. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 1999; 344: 109-116.
48. Stitt A, Hughes S-J, Canning P etal. Substrates modified by advanced glycation end-products cause dysfunction and death in retinal pericytes by reducing survival signals mediated by platelet-derived growth factor. Diabetologia 2004; 47: 1735-1746.
49. Stitt AW. Advanced glycation: an important pathological event in diabetic and age related ocular disease. Br J Ophthalmol 2001; 85: 746-753.
50. Stitt AW, Li YM, Gardiner TA, Bucala R, Archer DB, Vlassara H. Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. Am J Pathol 1997; 150: 523-531.
51. Lu M, Kuroki M, Amano S etal. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest 1998; 101: 1219-1224.
52. Vinores SA, Campochiaro PA, Williams EH, May EE, Green WR, Sorenson RL. Aldose reductase expression in human diabetic retina and retinal pigment epithelium. Diabetes 1988; 37: 1658-1664.
53. Nishikawa T, Edelstein D, Brownlee M. The missing link: a single unifying mechanism for diabetic complications. Kidney Int 2000; 58: S26-S30.
54. Kowluru RA, Koppolu P. Diabetes-induced activation of caspase-3 in retina: effect of antioxidant therapy. Free Radic Res 2002; 36: 993-999.
55. Boyer P, Krebs E. The Enzymes. Vol XVII, 'Control by Phosphorylation', Part A. San Diego: Academic Press, 1986.
56. Shiba T, Inoguchi T, Sportsman JR, Heath WF, Bursell S, King GL. Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. Am J Physiol Endocrinol Metab 1993; 265: E783-793.
57. Yerneni K, Bai W, Khan BV, Medford RM, Natarajan R. Hyperglycemia-induced activation of nuclear transcription factor kappaB in vascular smooth muscle cells. Diabetes 1999; 48: 855-864.
58. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820.
59. Takagi C, Bursell S-E, Lin Y-W etal. Regulation of retinal hemodynamics in diabetic rats by increased expression and action of endothelin-1. Invest Ophthalmol Vis Sci 1996; 37: 2504-2518.
60. Chibber R, Ben-Mahmud BM, Mann GE, Zhang JJ, Kohner EM. Protein kinase C β2-dependent phosphorylation of core 2 GlcNAc-T promotes leukocyte-endothelial cell adhesion a mechanism underlying capillary occlusion in diabetic retinopathy. Diabetes 2003; 52: 1519-1527.
61. Schröder S, Palinski W, Schmid-Schönbein G. Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. Am J Pathol 1991; 139: 81-100.
62. Miyamoto K, Khosrof S, Bursell S-E etal. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci U S A 1999; 96: 10836-10841.
63. Joussen AM, Murata T, Tsujikawa A, Kirchhof B, Bursell S-E, Adamis AP. Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol 2001; 158: 147-152.
64. Joussen AM, Poulaki V, Le ML etal. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J 2004; 18: 1450-1452.
65. Aiello LP, Avery RL, Arrigg PG etal. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-1487.
66. Nguyen QD, Tatlipinar S, Shah SM etal. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 2006; 142: 961-969. e4.
67. Group UPDS. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.
68. Lyons TJ, Jenkins AJ, Zheng D etal. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci 2004; 45: 910-918.
69. Casson R, Wood J, Osborne N. Hypoglycaemia exacerbates ischaemic retinal injury in rats. Br J Ophthalmol 2004; 88: 816-820.
70. Dahl-Jørgensen K, Brinchmann-Hansen O, Hanssen K, Sandvik L, Aagenaes O. Rapid tightening of blood glucose control leads to transient deterioration of retinopathy in insulin dependent diabetes mellitus: the Oslo study. Br Med J (Clin Res Ed) 1985; 290: 811-815.
71. Wong TY, Mitchell P. Hypertensive retinopathy. N Engl J Med 2004; 351: 2310-2317.
72. Tso M, Jampol L. Pathophysiology of hypertensive retinopathy. Ophthalmology 1982; 89: 1132-1145.
73. Mule G, Nardi E, Cottone S etal. Influence of metabolic syndrome on hypertension-related target organ damage. J Intern Med 2005; 257: 503-513.
74. Wong TY, Duncan BB, Golden SH etal. Associations between the metabolic syndrome and retinal microvascular signs: the Atherosclerosis Risk In Communities Study. Invest Ophthalmol Vis Sci 2004; 45: 2949-2954.
75. Li L-J, Cheung CY-L, Liu Y etal. Influence of blood pressure on retinal vascular caliber in young children. Ophthalmology 2011; 118: 1459-1465.
76. Gopinath B, Wang J, Kifley A, Tan A, Wong T, Mitchell P. Influence of blood pressure and body mass index on retinal vascular caliber in preschool-aged children. J Hum Hypertens 2013; 27: 523-528.
77. Gopinath B, Flood VM, Wang JJ etal. Carbohydrate nutrition is associated with changes in the retinal vascular structure and branching pattern in children. Am J Clin Nutr 2012; 95: 1215-1222.
78. Hayreh SS, Podhajsky PA, Zimmerman MB. Retinal artery occlusion: associated systemic and ophthalmic abnormalities. Ophthalmology 2009; 116: 1928-1936.
79. Mitchell P, Smith W, Chang A. Prevalence and associations of retinal vein occlusion in Australia: the Blue Mountains Eye Study. Arch Ophthalmol 1996; 114: 1243-1247.
80. Panton RW, Goldberg MF, Farber MD. Retinal arterial macroaneurysms: risk factors and natural history. Br J Ophthalmol 1990; 74: 595-600.
81. Wong TY, Larsen EKM, Klein R etal. Cardiovascular risk factors for retinal vein occlusion and arteriolar emboli: the Atherosclerosis Risk in Communities & Cardiovascular Health studies. Ophthalmology 2005; 112: 540-547.
82. Leung H, Wang J, Rochtchina E, Wong T, Klein R, Mitchell P. Dyslipidaemia and microvascular disease in the retina. Eye 2004; 19: 861-868.
83. Klein R, Sharrett AR, Klein BE etal. Are retinal arteriolar abnormalities related to atherosclerosis? The Atherosclerosis Risk in Communities Study. Arterioscler Thromb Vasc Biol 2000; 20: 1644-1650.
84. Keech A, Mitchell P, Summanen P etal. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007; 370: 1687-1697.
85. Age-Related EDSRG. Risk factors associated with age-related macular degeneration. Ophthalmology 2000; 107: 2224-2232.
86. Clemons T, Milton R, Klein R, Seddon J, Ferris F 3rd. Risk factors for the incidence of advanced age-related macular degeneration in the Age-Related Eye Disease Study (AREDS) AREDS Report No. 19. Ophthalmology 2005; 112: 533-539.
87. Chiu CJ, Milton RC, Gensler G, Taylor A. Association between dietary glycemic index and age-related macular degeneration in nondiabetic participants in the Age-Related Eye Disease Study. Am J Clin Nutr 2007; 86: 180-188.
88. Kaushik S, Wang JJ, Flood V etal. Dietary glycemic index and the risk of age-related macular degeneration. Am J Clin Nutr 2008; 88: 1104-1110.
89. Tan J, Mitchell P, Smith W, Wang JJ. Cardiovascular risk factors and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. Ophthalmology 2007; 114: 1143-1150.
90. van Leeuwen R, Ikram MK, Vingerling JR, Witteman JC, Hofman A, de Jong PT. Blood pressure, atherosclerosis, and the incidence of age-related maculopathy: the Rotterdam Study. Invest Ophthalmol Vis Sci 2003; 44: 3771-3777.
91. Levin LA, Danesh-Meyer HV. Hypothesis: a venous etiology for nonarteritic anterior ischemic optic neuropathy. Arch Ophthalmol 2008; 126: 1582-1585.
92. Hayreh SS, Zahoruk RM. Anterior ischemic optic neuropathy. Ophthalmologica 1981; 182: 13-28.
93. Arnold AC. Pathogenesis of nonarteritic anterior ischemic optic neuropathy. J Neuroophthalmol 2003; 23: 157-163.
94. Grunstein R, Wilcox I, Yang T-S, Gould Y, Hedner J. Snoring and sleep apnoea in men: association with central obesity and hypertension. Int J Obes Relat Metab Disord 1993; 17: 533-540.
95. Mojon DS, Hedges TR III, Ehrenberg B etal. Association between sleep apnea syndrome and nonarteritic anterior ischemic optic neuropathy. Arch Ophthalmol 2002; 120: 601-605.
96. Repka MX, Savino PJ, Schatz N, Sergott R. Clinical profile and long-term implications of anterior ischemic optic neuropathy. Am J Ophthalmol 1983; 96: 478-483.
97. Hayreh SS, Joos KM, Podhajsky PA, Long CR. Systemic diseases associated with nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1994; 118: 766-780.